切换至 "中华医学电子期刊资源库"
高级检索
中华脑科疾病与康复杂志(电子版)

中华脑科疾病与康复杂志(电子版) ›› 2023, Vol. 13 ›› Issue (01) : 51 -56. doi: 10.3877/cma.j.issn.2095-123X.2023.01.006

临床研究

胞磷胆碱对大脑中动脉缺血性脑卒中恢复期的疗效
胡飞龙1,†(), 路璐1   
  1. 1. 236800　安徽亳州，亳州市人民医院老年医学科
  • 收稿日期:2022-07-12 出版日期:2023-02-15
  • 通信作者: 胡飞龙

Effect of citicoline on the recovery period of middle cerebral artery ischemic stroke

Feilong Hu1,†(), Lu Lu1   

  1. 1. Department of Geriatrics, Bozhou People's Hospital, Bozhou 236800, China
  • Received:2022-07-12 Published:2023-02-15
  • Corresponding author: Feilong Hu
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

胡飞龙, 路璐. 胞磷胆碱对大脑中动脉缺血性脑卒中恢复期的疗效[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(01): 51-56.

Feilong Hu, Lu Lu. Effect of citicoline on the recovery period of middle cerebral artery ischemic stroke[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2023, 13(01): 51-56.

目的

探究胞磷胆碱联合常规西药对大脑中动脉缺血性脑卒中恢复期患者的治疗效果及对脑血流变化的影响。

方法

选取自2018年7月至2021年12月亳州市人民医院老年医学科收治的134例大脑中动脉缺血性脑卒中恢复期患者，按照随机数字表法分为试验组和常规组，每组67例。2组患者均服用西药（阿司匹林肠溶片、丁苯酞软胶囊）、实施常规康复训练及控制血压、血糖、血脂等，试验组在常规组基础上增加胞磷胆碱。对比2组患者治疗前后美国国立卫生研究院卒中量表（NIHSS）评分、大脑中动脉脑血流参数[平均脑血流速度（Vm）、脑血流量（CBF）、搏动指数（PI）、阻力指数（RI）]、血清炎性因子水平[白介素-6（IL-6）、单核细胞趋化蛋白-1（MCP-1）、超敏C-反应蛋白（hs-CRP）、肿瘤坏死因子α（TNF-α）]，临床疗效和不良反应发生率。

结果

治疗后2组患者NIHSS评分、大脑中动脉PI与RI以及血清IL-6、MCP-1、hs-CRP、TNF-α水平均低于治疗前，大脑中动脉Vm、CBF均高于治疗前，差异具有统计学意义（P<0.05）；治疗后试验组NIHSS评分、大脑中动脉PI与RI以及血清IL-6、MCP-1、hs-CRP、TNF-α水平均低于常规组，大脑中动脉Vm、CBF均高于常规组，差异具有统计学意义（P<0.05）。试验组NIHSS评分、大脑中动脉脑血流参数（Vm、CBF、PI、RI）和血清炎性因子（IL-6、MCP-1、hs-CRP、TNF-α）水平的治疗前后差值大于常规组，差异具有统计学意义（P<0.05）。试验组总有效率（94.03%）高于常规组（82.09%），差异具有统计学意义（P<0.05）。2组患者不良反应发生率比较差异无统计学意义（P>0.05）。

结论

对大脑中动脉缺血性脑卒中恢复期患者采用胞磷胆碱联合其他西药进行治疗能降低神经功能缺损评分与炎性因子水平，并可改善大脑中动脉脑血流，提升临床疗效，且安全性好。

关键词: 大脑中动脉, 缺血性脑卒中, 恢复期, 胞磷胆碱, 脑血流, 炎性因子
Objective

To explore the efficacy of citicoline combined with conventional western medicine in convalescence patients with middle cerebral artery ischemic stroke and its influence on cerebral blood flow.

Methods

One hundred and thirty-four conventional patients with middle cerebral artery ischemic stroke from July 2018 to December 2021 admitted in Geriatrics Department of Bozhou People's Hospital were selected, and they were divided into the experimental group and the conventional group through the random number table, with 67 cases in each group. Both groups were given western medicine (aspirin enteric-coated tablets, butylphthalide soft capsules), carried out routine rehabilitation training and controlled blood pressure, blood glucose and blood lipid, while citicoline were added to the experimental group on the basis of the conventional group. The National Institute of Health stroke scale (NIHSS) scores, the changes of cerebral blood flow parameters of middle cerebral artery [mean cerebral blood flow velocity (Vm), mean cerebral blood flow (CBF), pulsatility index (PI), resistance index (RI)] and the levels of serum inflammatory factors [interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), high sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α)] before and after treatment, clinical efficacy and the incidences of adverse reactions were compared between the two groups.

Results

After treatment, the NIHSS scores, PI and RI of middle cerebral artery and the levels of serum IL-6, MCP-1, hs-CRP and TNF-α of the two groups were lower than those before treatment, but the Vm and CBF of middle cerebral artery were higher than those before treatment (P<0.05). After treatment, the NIHSS score, PI and RI of middle cerebral artery and the levels of serum IL-6, MCP-1, hs-CRP and TNF-α in the experimental group were lower than those in the conventional group (P<0.05), but the Vm and CBF of middle cerebral artery were higher than those in the conventional group (P < 0.05). The D-values before and after treatment of the NIHSS score, blood flow parameters of middle cerebral artery (Vm, CBF, PI, RI) and serum inflammatory factors (IL-6, MCP-1, hs-CRP, TNF-α) in the experimental group were greater than those in the conventional group (P<0.05). The total effective rate of the experimental group (94.03%) was higher than that of the conventional group (82.09%) (P<0.05). There was no significant difference in the incidence of adverse reactions between the both groups (P>0.05).

Conclusion

Citicoline combined with other western medicine in the treatment of convalescence patients with middle cerebral artery ischemic stroke can reduce neurological deficit scores and inflammatory factor levels, improve the cerebral blood flow of middle cerebral artery, enhance clinical efficacy, and have good safety.

Key words: Middle cerebral artery, Cerebral ischemic stroke, Convalescence, Citicoline, Cerebral blood flow, Inflammatory factors
表1 2组患者的一般资料比较
Tab.1 Comparison of general data between two groups
资料 试验组（n=67） 常规组（n=67） χ2/t/Z值 P值
性别     0.135 0.713
男 44 46    
女 23 21    
年龄（岁，Mean±SD） 67.19±7.65 68.49±7.01 1.026 0.307
病程（d，Mean±SD） 62.16±11.83 63.45±12.57 0.612 0.542
体质量指数（kg/m2，Mean±SD） 22.31±2.41 22.46±2.39 0.362 0.718
Holden步行能功分级     0.369 0.682
1级 5 6    
2级 12 13    
3级 16 16    
4级 22 20    
5级 12 12    
合并症        
高血压 34 32 0.119 0.730
2型糖尿病 23 21 0.135 0.713
高脂血症 35 34 0.030 0.863
表2 2组患者治疗前后NIHSS评分比较（分，Mean±SD）
Tab.2 Comparison of NIHSS scores between two groups before and after treatment (score, Mean±SD)
组别 例数 治疗前 治疗后 t值 P值
试验组 67 13.93±3.05 5.37±0.85 22.129 <0.001
常规组 67 13.84±3.01 5.91±1.08 20.298 <0.001
t值   0.172 3.216    
P值   0.864 0.002    
表3 2组患者的临床疗效比较[例（%）]
Tab.3 Comparison of clinical efficacy between two groups [n(%)]
组别 例数 痊愈 显效 进步 无效 加重 总有效率
试验组 67 30（44.78） 19（28.36） 14（20.90） 4（5.97） 0（0.00） 63（94.03）
常规组 67 27（40.30） 15（22.39） 13（19.40） 12（17.91） 0（0.00） 55（82.09）
Z/χ2值       4.785     4.542
P值       0.031     0.033
表4 2组患者治疗前后大脑中动脉脑血流变化情况比较（Mean±SD）
Tab.4 Comparison of changes in cerebral blood flow of the middle cerebral artery between two groups before and after treatment (Mean±SD)
指标   试验组（n=67） 常规组（n=67） t值 P值
Vm（cm/s） 治疗前 69.93±10.02 70.25±9.84 0.187 0.852
治疗后 93.15±11.17 89.36±10.28 2.044 0.043
t值 12.666 10.992    
P值 <0.001 <0.001    
CBF[mL/（s·100 g）] 治疗前 464.17±43.08 466.85±43.24 0.359 0.720
治疗后 602.01±63.19 578.31±62.85 2.177 0.031
t值 14.753 11.959    
P值 <0.001 <0.001    
PI 治疗前 1.27±0.21 1.24±0.23 0.788 0.432
治疗后 0.88±0.15 0.93±0.12 2.131 0.035
t值 12.370 9.781    
P值 <0.001 <0.001    
RI 治疗前 1.06±0.14 1.03±0.12 1.332 0.185
治疗后 0.68±0.12 0.73±0.14 2.220 0.028
t值 16.869 13.317    
P值 <0.001 <0.001    
表5 2组患者治疗前后的血清炎性因子水平变化情况比较（Mean±SD）
Tab.5 Comparison of changes in serum inflammatory factor levels before and after treatment between two groups (Mean±SD)
指标   试验组（n=67） 常规组（n=67） t值 P值
IL-6（ng/L） 治疗前 336.41±50.38 325.19±52.47 1.263 0.209
治疗后 221.03±38.42 237.64±41.15 2.415 0.017
t值 14.908 10.747    
P值 <0.001 <0.001    
MCP-1（pg/mL） 治疗前 145.82±20.69 143.07±20.13 0.780 0.437
治疗后 96.73±11.64 101.62±13.47 2.248 0.026
t值 16.926 14.008    
P值 <0.001 <0.001    
hs-CRP（mg/L） 治疗前 17.48±3.05 17.19±3.01 0.554 0.581
治疗后 5.73±1.15 6.23±1.24 2.420 0.017
t值 29.506 27.558    
P值 <0.001 <0.001    
TNF-α（ng/L） 治疗前 531.69±75.61 527.38±77.26 0.326 0.745
治疗后 383.74±63.85 409.13±62.18 2.332 0.021
t值 12.237 9.760    
P值 <0.001 <0.001    
[1]
魏淑琦,孟心怡,阎文静,等.急性轻型缺血性脑卒中患者扩大的血管周围间隙与脑卒中后认知功能障碍的相关性[J].中华神经医学杂志, 2022, 21(1): 20-27. DOI: 10.3760/cma.j.cn115354-20210926-00631.
[2]
Langsted A, Nordestgaard BG, Kamstrup PR. Elevated lipoprotein (a) and risk of ischemic stroke[J]. J Am Coll Cardiol, 2019, 74(1): 54-66. DOI: 10.1016/j.jacc.2019.03.524.
[3]
Branco JP, Oliveira S, Sargento-Freitas J, et al. Assessing functional recovery in the first six months after acute ischemic stroke: a prospective, observational study[J]. Eur J Phys Rehabil Med, 2019, 55(1): 1-7. DOI: 10.23736/S1973-9087.18.05161-4.
[4]
Bansal A, Prathap R, Gupta S, et al. Role of microRNAs in stroke recovery[J]. J Family Med Prim Care, 2019, 8(6): 1850-1854. DOI: 10.4103/jfmpc.jfmpc_296_19.
[5]
Pan Y, Elm JJ, Li H, et al. Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: a pooled analysis of clopidogrel in high-risk patients with acute non-disabling cerebrovascular events (chance) and platelet-oriented inhibition in new tia and minor ischemic stroke (point) trials[J]. JAMA Neurol, 2019, 76(12): 1466-1473. DOI: 10.1001/jamaneurol.2019.2531.
[6]
Tramacere I, Boncoraglio GB, Banzi R, et al. Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis[J]. BMC Med, 2019, 17(1): 67. DOI: 10.1186/s12916-019-1298-5.
[7]
Lv J, Zhao D, Zhao G, et al. Efficacy and safety of butylphthalide in secondary prevention of stroke: study protocol for a multicenter, real world trial based on Internet[J]. BMC Neurol, 2022, 22(1): 305. DOI: 10.1186/s12883-022-02815-x.
[8]
Danarto R, Heriyanto DS, Risan M, et al. Lumbrokinase effects on pro-and anti-apoptotic gene expression in Wistar rats with testicular torsion[J]. Res Rep Urol, 2019, 11(2): 249-254. DOI: 10.2147/RRU.S212431.
[9]
Nakazaki E, Yabuki Y, Izumi H, et al. Combined citicoline and docosahexaenoic acid treatment improves cognitive dysfunction following transient brain ischemia[J]. J Pharmacol Sci, 2019, 139(4): 319-324. DOI: 10.1016/j.jphs.2019.02.003.
[10]
中华医学会.临床治疗指南·神经病学分册[M].北京:人民卫生出版社, 2006: 12-13.
[11]
Chalos V, van der Ende NAM, Lingsma HF, et al. National Institutes of Health Stroke Scale: an alternative primary outcome measure for trials of acute treatment for ischemic stroke[J]. Stroke, 2020, 51(1): 282-290. DOI: 10.1161/STROKEAHA.119.026791.
[12]
孙明,王蔚文.临床疾病诊断与疗效判断标准[M].北京:科学技术文献出版社, 2010: 180-181.
[13]
Belova AN, Bogdanov EI, Voznyuk IA, et al. Therapy of moderate cognitive impairment in the early recovery period of ischemic stroke[J]. Zh Nevrol Psikhiatr Im S S Korsakova, 2021, 121(5): 33-39. DOI: 10.17116/jnevro202112105133.
[14]
Jayaraj RL, Azimullah S, Beiram R, et al. Neuroinflammation: friend and foe for ischemic stroke[J]. J Neuroinflammation, 2019, 16(1): 142. DOI: 10.1186/s12974-019-1516-2.
[15]
Stanzione R, Cotugno M, Bianchi F, et al. Pathogenesis of ischemic stroke: role of epigenetic mechanisms[J]. Genes (Basel), 2020, 11(1): 89. DOI: 10.3390/genes11010089.
[16]
冯红选,桂千,吴冠会,等.银杏二萜内酯葡胺注射液联合阿司匹林治疗大动脉粥样硬化型缺血性脑卒中的临床疗效[J].中国老年学杂志, 2020, 40(15): 3158-3161. DOI: 10.3969/j.issn.1005-9202.2020.15.008.
[17]
Palazzo P, Ingrand P, Agius P, et al. Transcranial doppler to detect right-to-left shunt in cryptogenic acute ischemic stroke[J]. Brain Behav, 2019, 9(1): e01091. DOI: 10.1002/brb3.1091.
[18]
Gupta V, Bader ZE, Aakriti, et al. Possible pharmacodynamic interaction of azelnidipine with citicoline against ischemic brain injury: behavioral, biochemical and histological alterations[J]. Ann Neurosci, 2020, 27(1): 9-17. DOI: 10.1177/0972753120932475.
[19]
Webb AJS, Paolucci M, Mazzucco S, et al. Confounding of cerebral blood flow velocity by blood pressure during breath holding or hyperventilation in transient ischemic attack or stroke[J]. Stroke, 2020, 51(2): 468-474. DOI: 10.1161/STROKEAHA.119.027829.
[20]
董贞.炎性细胞因子在急性缺血性脑梗死尿激酶静脉溶栓治疗患者中的变化[J].河北医药, 2019, 41(1): 92-95. DOI: 10.3969/j.issn.1002-7386.2019.01.022.
[21]
齐金秋,宫琨,朱庆慧.葛酮通络胶囊联合丁苯酞治疗急性脑梗死的临床研究[J].现代药物与临床, 2019, 34(1): 36-40. DOI: 10.7501/j.issn.1674-5515.2019.01.008.
[22]
Synoradzki K, Grieb P. Citicoline: a superior form of choline[J]. Nutrients, 2019, 11(7): 1569. DOI: 10.3390/nu11071569.
[23]
Safavi M, Hosseini-Sharifabad A, Seyed-Yousefi Y, et al. Protective effects of citicoline and benfotiamine each alone and in combination on streptozotocin-induced memory impairment in mice[J]. Clin Psychopharmacol Neurosci, 2020, 18(1): 81-92. DOI: 10.9758/cpn.2020.18.1.81.
[24]
杨丽英,李红英.丁苯酞注射液联合胞磷胆碱钠治疗缺血性脑卒中的疗效及对患者认知功能的影响[J].海南医学, 2021, 32(7): 835-839. DOI: 10.3969/j.issn.1003-6350.2021.07.005.
[25]
Martí-Carvajal AJ, Valli C, Martí-Amarista CE, et al. Citicoline for treating people with acute ischemic stroke[J]. Cochrane Database Syst Rev, 2020, 8(8): CD013066. DOI: 10.1002/14651858.CD013066.pub2.
[1] 魏淑婕, 惠品晶, 丁亚芳, 张白, 颜燕红, 周鹏, 黄亚波. 单侧颈内动脉闭塞患者行颞浅动脉-大脑中动脉搭桥术的脑血流动力学评估[J]. 中华医学超声杂志（电子版）, 2023, 20(10): 1046-1055.
[2] 袁泽, 庄丽. 超声检测胎儿脐动脉和大脑中动脉血流对胎儿宫内窘迫的诊断价值[J]. 中华医学超声杂志（电子版）, 2023, 20(06): 618-621.
[3] 高文伯, 李明, 张运昊. 进展期肺癌炎症指数对三阴性乳腺癌的预后价值和临床意义[J]. 中华乳腺病杂志(电子版), 2023, 17(04): 210-217.
[4] 钱晓英, 吴新, 徐婷婷. 颅脑损伤并发呼吸衰竭患者早期机械通气的效果分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 526-528.
[5] 尚慧娟, 袁晓冬. 机械取栓术后应用依达拉奉右崁醇对急性缺血性脑卒中预后的改善[J]. 中华神经创伤外科电子杂志, 2023, 09(05): 295-301.
[6] 黎鹏程, 黄谦亦, 张逵, 范润金, 尚彬. 手术切除颅内巨大假性动脉瘤一例报道并文献复习[J]. 中华神经创伤外科电子杂志, 2023, 09(02): 123-125.
[7] 任香凝, 郑晓明. 缺血性脑卒中与外周免疫应答的研究进展[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(03): 175-179.
[8] 王姗姗, 徐小汝, 史振仙, 张德杰. 丹参多酚酸联合尤瑞克林治疗急性分水岭脑梗死的疗效及对认知功能、脑血流动力学和血清LPA、ox-LDL、MMP-9水平的影响[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(03): 142-149.
[9] 张许平, 刘佳成, 张舸, 杜艳姣, 李韶, 商丹丹, 王浩, 李艳, 段智慧. CYP2C19基因多态性联合血栓弹力图指导大动脉粥样硬化型非致残性缺血性脑血管事件患者抗血小板治疗的效果[J]. 中华脑血管病杂志(电子版), 2023, 17(05): 477-481.
[10] 邓颖, 黄山, 胡慧秀, 孙超. 老年缺血性脑卒中患者危险因素聚集情况分析[J]. 中华脑血管病杂志(电子版), 2023, 17(04): 344-349.
[11] 李昕, 李永凯, 江树青, 夏来百提姑·赛买提, 杨建中. 急性缺血性脑卒中静脉溶栓后出血转化相关危险因素分析[J]. 中华脑血管病杂志(电子版), 2023, 17(04): 331-336.
[12] 李永凯, 吐尔洪·吐尔逊, 杨建中. 开颅术后患者大脑中动脉的经颅多普勒超声测量值与意识评分、血生化指标的相关性[J]. 中华脑血管病杂志(电子版), 2023, 17(03): 221-226.
[13] 黎丹丹, 程峙娟, 刘旭, 陈未平, 殷敏, 郭华, 涂江龙. 急性后循环进展性缺血性卒中患者血管内治疗的效果[J]. 中华脑血管病杂志(电子版), 2023, 17(02): 112-123.
[14] 俞刘珍雄, 张康睿, 杨若蕊, 刘学春, 王龙, 吴竹青, 吴君仓. 维生素D水平与接受静脉溶栓治疗的缺血性卒中患者预后的关系[J]. 中华脑血管病杂志(电子版), 2023, 17(02): 94-101.
[15] 邱佳敏, 蒋惠怡, 陶涛. 丹参酮ⅡA治疗急性缺血性脑卒中动物模型效果的Meta分析[J]. 中华脑血管病杂志(电子版), 2023, 17(02): 136-144.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号